Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TXMD
stocks logo

TXMD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for TherapeuticsMD Inc (TXMD.O) is 10.06, compared to its 5-year average forward P/E of -0.19. For a more detailed relative valuation and DCF analysis to assess TherapeuticsMD Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.19
Current PE
10.06
Overvalued PE
9.75
Undervalued PE
-10.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.31
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.04
Undervalued EV/EBITDA
-4.67

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.99
Current PS
0.00
Overvalued PS
8.95
Undervalued PS
-0.97
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

TXMD News & Events

Events Timeline

(ET)
2025-11-12
16:14:37
TherapeuticsMD Announces Q3 Earnings Per Share of 0c Compared to (5c) Last Year
select
2025-08-12 (ET)
2025-08-12
16:36:09
TherapeuticsMD reports Q2 EPS 5c vs. (9c) last year
select
2025-05-13 (ET)
2025-05-13
16:13:37
TherapeuticsMD reports Q1 EPS (6c) vs. (7c) last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
08-13NASDAQ.COM
TherapeuticsMD Swings to Profit in Q2

  • Financial Performance: TherapeuticsMD reported a net income of $545 thousand for Q2 2025, a significant improvement from a loss of $1.05 million in the same quarter last year, driven by increased license revenue which rose to $1.0 million and a 45.5% reduction in operating expenses.

  • Business Model Transition: The company has fully transitioned to a royalty-focused business model, relying on licensing agreements with partners like Mayne Pharma for revenue, while ceasing its own research and development efforts, leading to a focus on cash preservation and operational efficiency.

[object Object]
Preview
9.5
08-13NASDAQ.COM
TherapeuticsMD Q2 Earnings Summary

  • Earnings Performance: TherapeuticsMD reported earnings of $0.55 million in Q2, a significant improvement from a loss of $1.05 million in the same quarter last year.

  • Earnings Per Share (EPS): The company achieved an EPS of $0.05 in Q2, compared to a loss of $0.09 per share during the same period last year.

[object Object]
Preview
9.5
03-26Benzinga
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

  • GameStop Earnings Report: GameStop Corp. shares rose 13.4% in pre-market trading after reporting fourth-quarter adjusted earnings of 30 cents per share, exceeding analyst expectations, despite revenue falling short of estimates at $1.283 billion.

  • Pre-Market Stock Movements: Several stocks saw significant gains in pre-market trading, including Theratechnologies Inc. (+88.3%) and SurgePays, Inc. (+69.5%), while others like Golden Heaven Group Holdings Ltd. (-24.4%) and Humacyte, Inc. (-22.1%) experienced notable declines.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is TherapeuticsMD Inc (TXMD) stock price today?

The current price of TXMD is 1.61 USD — it has increased 1.26 % in the last trading day.

arrow icon

What is TherapeuticsMD Inc (TXMD)'s business?

TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).

arrow icon

What is the price predicton of TXMD Stock?

Wall Street analysts forecast TXMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TXMD is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is TherapeuticsMD Inc (TXMD)'s revenue for the last quarter?

TherapeuticsMD Inc revenue for the last quarter amounts to 784.00K USD, increased 43.33 % YoY.

arrow icon

What is TherapeuticsMD Inc (TXMD)'s earnings per share (EPS) for the last quarter?

TherapeuticsMD Inc. EPS for the last quarter amounts to 0.01 USD, decreased -120.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for TherapeuticsMD Inc (TXMD)'s fundamentals?

The market is revising No Change the revenue expectations for TXMD for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 49.07%.
arrow icon

How many employees does TherapeuticsMD Inc (TXMD). have?

TherapeuticsMD Inc (TXMD) has 1 emplpoyees as of December 05 2025.

arrow icon

What is TherapeuticsMD Inc (TXMD) market cap?

Today TXMD has the market capitalization of 18.63M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free